BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22503806)

  • 21. Long-term outcome of multimodal therapy for giant prolactinomas.
    Andujar-Plata P; Villar-Taibo R; Ballesteros-Pomar MD; Vidal-Casariego A; Pérez-Corral B; Cabezas-Agrícola JM; Álvarez-Vázquez P; Serramito R; Bernabeu I
    Endocrine; 2017 Jan; 55(1):231-238. PubMed ID: 27704480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.
    Mohan N; Chia YY; Goh GH; Ting E; Teo K; Yeo TT
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29102970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prolactinoma].
    Krysiak R; Okopień B; Marek B; Szkróbka W
    Przegl Lek; 2009; 66(4):198-205. PubMed ID: 19708510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
    Burlacu MC; Maiter D; Duprez T; Delgrange E
    Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolactinomas in children and adolescents--consequences in adult life.
    Duntas LH
    J Pediatr Endocrinol Metab; 2001; 14 Suppl 5():1227-32; discussion 1261-2. PubMed ID: 11964017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of resistant prolactinomas.
    Olafsdottir A; Schlechte J
    Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of prolactinomas during pregnancy.
    Witek P; Zieliński G
    Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Some issues in the diagnosis and treatment of hyperprolactinemia].
    Jin ZM
    Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):241-3. PubMed ID: 18843959
    [No Abstract]   [Full Text] [Related]  

  • 30. Non-surgical management of cystic prolactinomas.
    Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
    J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Italian Guidelines for the Management of Prolactinomas.
    Cozzi R; Simona Auriemma R; De Menis E; Esposito F; Ferrante E; Iatì G; Mazzatenta D; Poggi M; Rudà R; Tortora F; Cruciani F; Mitrova Z; Saulle R; Vecchi S; Basile M; Cappabianca P; Paoletta A; Papini E; Persichetti A; Samperi I; Scoppola A; Bozzao A; Caputo M; Doglietto F; Ferraù F; Lania AG; Laureti S; Lello S; Locatelli D; Maffei P; Minniti G; Peri A; Ruini C; Settanni F; Silvani A; Veronese N; Grimaldi F; Attanasio R
    Endocr Metab Immune Disord Drug Targets; 2023; 23(12):1459-1479. PubMed ID: 37171003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.
    Almalki MH; Buhary B; Alzahrani S; Alshahrani F; Alsherbeni S; Alhowsawi G; Aljohani N
    Pituitary; 2015 Jun; 18(3):405-9. PubMed ID: 25062894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term management of prolactinomas.
    Schlechte JA
    J Clin Endocrinol Metab; 2007 Aug; 92(8):2861-5. PubMed ID: 17682084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolactinomas.
    Wildemberg LE; Fialho C; Gadelha MR
    Presse Med; 2021 Dec; 50(4):104080. PubMed ID: 34687915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperprolactinemia and prolactinomas.
    Mancini T; Casanueva FF; Giustina A
    Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy.
    Colao A; Di Sarno A; Guerra E; Pivonello R; Cappabianca P; Caranci F; Elefante A; Cavallo LM; Briganti F; Cirillo S; Lombardi G
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):426-33. PubMed ID: 17573902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transsphenoidal microsurgical results of female patients with prolactinomas.
    Ikeda H; Watanabe K; Tominaga T; Yoshimoto T
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1621-5. PubMed ID: 23498159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma.
    Molitch ME
    Eur J Endocrinol; 2015 May; 172(5):R205-13. PubMed ID: 25805896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
    Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
    Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.